Nature Communications (Jul 2020)
Combining PARP with ATR inhibition overcomes PARP inhibitor and platinum resistance in ovarian cancer models
- Hyoung Kim,
- Haineng Xu,
- Erin George,
- Dorothy Hallberg,
- Sushil Kumar,
- Veena Jagannathan,
- Sergey Medvedev,
- Yasuto Kinose,
- Kyle Devins,
- Priyanka Verma,
- Kevin Ly,
- Yifan Wang,
- Roger A. Greenberg,
- Lauren Schwartz,
- Neil Johnson,
- Robert B. Scharpf,
- Gordon B. Mills,
- Rugang Zhang,
- Victor E. Velculescu,
- Eric J. Brown,
- Fiona Simpkins
Affiliations
- Hyoung Kim
- Penn Ovarian Cancer Research Center, Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Pennsylvania
- Haineng Xu
- Penn Ovarian Cancer Research Center, Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Pennsylvania
- Erin George
- Penn Ovarian Cancer Research Center, Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Pennsylvania
- Dorothy Hallberg
- The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine
- Sushil Kumar
- Penn Ovarian Cancer Research Center, Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Pennsylvania
- Veena Jagannathan
- Department of Cancer Biology, Perelman School of Medicine, University of Pennsylvania
- Sergey Medvedev
- Penn Ovarian Cancer Research Center, Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Pennsylvania
- Yasuto Kinose
- Penn Ovarian Cancer Research Center, Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Pennsylvania
- Kyle Devins
- Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania
- Priyanka Verma
- Department of Cancer Biology, Perelman School of Medicine, University of Pennsylvania
- Kevin Ly
- Penn Ovarian Cancer Research Center, Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Pennsylvania
- Yifan Wang
- Molecular Therapeutics Program, Fox Chase Cancer Center
- Roger A. Greenberg
- Department of Cancer Biology, Perelman School of Medicine, University of Pennsylvania
- Lauren Schwartz
- Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania
- Neil Johnson
- Molecular Therapeutics Program, Fox Chase Cancer Center
- Robert B. Scharpf
- The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine
- Gordon B. Mills
- Department of Cell, Developmental and Cancer Biology, Oregon Health & Science University School of Medicine
- Rugang Zhang
- Gene Expression and Regulation Program, The Wistar Institute
- Victor E. Velculescu
- The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine
- Eric J. Brown
- Department of Cancer Biology, Perelman School of Medicine, University of Pennsylvania
- Fiona Simpkins
- Penn Ovarian Cancer Research Center, Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Pennsylvania
- DOI
- https://doi.org/10.1038/s41467-020-17127-2
- Journal volume & issue
-
Vol. 11,
no. 1
pp. 1 – 16
Abstract
Patients with ovarium cancer frequently develop resistance to platinum chemotherapy and PARP inhibitors (PARPi). Here, the authors show that the combination of PARP and ATR inhibitors increases the therapeutic response in PARPi and platinum resistant ovarium cancer PDX models.
